In the Lab By Sharon Begley New CRISPR tool has the potential to correct almost all disease-causing DNA glitches, scientists report
The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein Listen: Pharma’s future in China, CRISPR meets Netflix, & where VC dollars come from
In the Lab By Olga Dobrovidova Calling embryo editing ‘premature,’ Russian authorities seek to ease fears of a scientist going rogue
In the Lab By Rebecca Robbins Major error undermines study suggesting change introduced in the CRISPR babies experiment shortens lives
The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein Listen: Vaping upheaval, DNA test dynamics, & the future of genome editing
Health By Sharon Begley ‘I just want to live’: California man pleads with scientists around the world to ‘CRISPR me’
First Opinion By Francoise Baylis Before heritable genome editing, we need slow science and dialogue ‘within and across nations’
Health By Andrew Joseph Could editing the DNA of embryos with CRISPR help save people who are already alive?
Health By Sharon Begley In a CRISPR first, therapy intended to cure HIV patient appears safe — though ineffective
In the Lab By Sharon Begley Why so many cancer drugs fail: Genes thought ‘essential’ for tumor survival are not, study finds
Business By Sharon Begley Battleground narrowed in CRISPR patent case between University of California and Broad
In the Lab By Sharon Begley For rules on creating ‘CRISPR babies’ from edited embryos, scientists call a do-over
Exclusive By Sharon Begley Fight for coveted CRISPR patents gets knottier, as MilliporeSigma makes new claims
Pharmalot By Elizabeth Cooney Pharmalittle: Canada throws cold water on U.S. drug importation; was FDA’s ‘smart pill’ approval smart?
Politics By Andrew Joseph Following ‘CRISPR babies’ scandal, senators call for international gene editing guidelines
In the Lab By Andrew Joseph A family’s medical mystery sheds light on the surprising ways disease-causing genes can be inherited
The Readout LOUD By Damian Garde and Adam Feuerstein Listen: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing
Pharmalot By Ed Silverman Pharmalittle: Judge appears to back push for opioid settlement; the CRISPR patent fight lives on
Biotech By Rebecca Robbins Architects of a new CRISPR partnership defend academic-industry research model
The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein Listen: Biohacking meets bureaucracy, and the latest twist in CRISPR world
